ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1564

Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study

Paola Estefania Bermudez Bermejo1, RODOLFO JIMENEZ-SOTO1, Alain Sanchez-Rodríguez1, Alonso Turrent1, Daniela Mercado- Velasco1, Ian Bravo-Lee1, Mariana Berenice Colli-Cortés2, Everardo Alvarez Hernandez3 and MaryCarmen Amigo1, 1CENTRO MEDICO ABC, Mexico City, Mexico, 2Hospital Regional "General Ignacio Zaragoza" ISSSTE, Mexico City, Mexico, 3HOSPITAL GENERAL DE MEXICO, Mexico City, Mexico

Meeting: ACR Convergence 2021

Keywords: COVID-19, Inflammation, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Infection-related Rheumatic Disease Poster (1530–1564)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Nailfold capillaroscopy is a relatively easy-to-access, low-cost clinical tool that could help identify early coagulopathy in subjects with SARS-CoV-2, but specific findings vs. controls and its possible prognostic role has not been studied.

Methods: We designed a cross-sectional study, carried out in a single care center for critical patients with SARS-CoV-2 pneumonia at the ABC Medical Center, Mexico City, which included patients from an intensive care unit (ICU) and internal medicine ward from March to April 2020. Demographic, biochemical and clinical features were collected. All patients signed the informed consent and the study was approved by the hospital ethics committee. All patients underwent nail capillary imaging of the 3 central fingers of each hand with a portable microscope with 100x magnification coupled to a smartphone with 7 megapixel images in an immersion medium. Capillaroscopy was performed in patients who didn´t have fever or hypothermia, or need vasopressors at the time of evaluation. Control subjects are healthy subjects matched on age and sex from a database of healthy controls without rheumatic diseases. Image evaluation of COVID-19 patients was performed in a blinded way for their characteristics. Prior to the analysis, a pilot test was obtained with 4 rheumatologists in random cases, obtaining an acceptable global agreement in the visualization of capillaries and alterations. (Kappa=0.58, p=0.0019). Obtained data from capillaroscopies were used to be compared between severe and moderate cases of COVID-19. Additionally, we compared the findings against a healthy population in order to establish a reference.

Results: We included data from 27 patients and 32 controls with similar demographic features. Patients with COVID-19 patients had a mean age of 43 +/- 13.8 years, 63% female. Comorbidities were present in 44.4% with: type 2 Diabetes Mellitus 18.5%, systemic hypertension 18.5%, and rheumatoid arthritis 3.7%. The mean length of stay time was 13 +/- 7.1 days, 48.1% were admitted to the ICU, and 40.7% required invasive mechanical ventilation. In the capillaroscopic review remarkable findings of patients vs. controls were hemosiderin deposits (33 vs 12.5%, p=0.05), less frequently observable capillaries (77 vs 100%, p=0.005), any abnormality in capillaries (25.9 vs. 6.3%, p=0.03). Of notice, specific findings in COVID-19 patients were capillary tortuosities in 19%, dilatation 9.5%, serpentine pattern 4.8%, bush pattern 9.5% and decreased density in only 4.8% of the cases. Avascular areas or capillaries of neoformation were not observed. The presence of hemosiderin was associated with worse presentation and risk factors for severe COVID-19: male sex 66.7 vs. 27.8%, (p = 0.024); Admission to ICU 77% vs 33% (p = 0.029); obesity 66.7 vs. 27.8% (p = 0.053). And risk for ICU admission OR = 7.0 (95% CI 1.098 – 44.6).

Conclusion: We present one of the first reports of nailfold capillaroscopic findings in COVID- 19 and the first to compare to healthy controls. Previous data suggests the presence of endothelial dysfunction and microvascular complications such as micro hemorrhage or micro thrombosis. Further studies may confirm these findings and prognostic value for worse outcomes in this illness.

NC COVID19.jpeg”Description: A. Extensive NB hemorrhage. B. Deposition of hemosiderin in multiple capillaries of the NB. C. Linear deposition of hemosiderin in the NB. D and E. Deposition of hemosiderin in some capillaries in the NB. F. Extensive hemorrhage accompanied by hemosiderin deposition in a large area of the NB.


Disclosures: P. Bermudez Bermejo, None; R. JIMENEZ-SOTO, None; A. Sanchez-Rodríguez, None; A. Turrent, None; D. Mercado- Velasco, None; I. Bravo-Lee, None; M. Colli-Cortés, None; E. Alvarez Hernandez, None; M. Amigo, None.

To cite this abstract in AMA style:

Bermudez Bermejo P, JIMENEZ-SOTO R, Sanchez-Rodríguez A, Turrent A, Mercado- Velasco D, Bravo-Lee I, Colli-Cortés M, Alvarez Hernandez E, Amigo M. Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/nailfold-capillaroscopy-characterization-in-covid-19-a-case-control-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nailfold-capillaroscopy-characterization-in-covid-19-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology